Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 349

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 349
---
 and personal traits. These results can be viewed on Rewell’s secure digital platform, where consumers can also, in certain circumstances, schedule a telemedicine consultation with a health care professional to interpret their results, and also receive a health plan with recommendations to target the prevention of certain health issues and health objectives. On January 9, 2024, OmnigenicsAI was incorporated in the Cayman Islands. On February 26, 2024, the Parent entered into a contribution agreement with OmnigenicsAI, pursuant to which Parent contributed to OmnigenicsAI all of the issued and outstanding shares in Heritas Argentina, making Heritas Argentina a wholly owned subsidiary of OmnigenicsAI. OmnigenicsAI issued 30,000,000 Company Shares to Parent in connection with the Heritas Argentina contribution. Our Operating Segments We operate across two segments within our corporate structure, dedicated to providing precise and secure biological data to empower individuals to make informed health choices. Our business units operate at the forefront of scientific development, genetic testing and will be integrated with AI -driventechnology, designed to address the entire spectrum of healthcare needs, spanning prevention diagnosis and prognosis, integrating a wide range of clinical, biological, and lifestyle data. The services within these segments have been developed based on our experience in the Latin American region, allowing us to adapt our tests and results based on the local language and specific needs. With a focus on precision, privacy, and accessibility, OmnigenicsAI is committed to empowering individuals and healthcare providers with the tools necessary for proactive health management through the following categories with its current brands: • Rewell: personalized wellness and preventative health solutions that integrate genetic, microbiome and lifestyle data, with nutrigenetic guidance tailored to each user. Through our digital platform, users access DNA and gut microbiome testing, paired with personalized health recommendations designed to empower individuals in making informed health decisions, particularly for chronic disease prevention and gut health. Rewell’s services include consultations with certified nutrigenetic specialists, who guide users in adopting lifestyle changes based on genetic and microbiome insights.; and 179 •Heritas Diagnostics: a suite of clinical genetic testing services focused on reproductive health, oncology, rare diseases, and clinical gut health. Our tests integrate genetic and clinical data to provide precise and actionable insights that support accurate diagnoses, effective monitoring and informed treatment decisions. We ensure that our comprehensive clinical reports deliver the necessary insights needed by both patients and physicians to interpret results and make informed treatment decisions. Rewell: Wellness and Prevention